Dr. Daniel Hertz

Biography

Daniel L Hertz received his PharmD from the Ernest Mario School of Pharmacy at Rutgers University in 2008 and his PhD in Pharmaceutical Sciences from the UNC Eshelman School of Pharmacy in 2013. He is an Associate Professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy. His research focuses on cancer pharmacogenetics, and during his doctoral studies, he worked with Dr. Howard McLeod, where he introduced the field of cancer pharmacogenetics. His dissertation research centered on the discovery and validation of pharmacogenetic predictors of taxane-induced neuropathy. Dr. Hertz is engaged in developing tools for individualizing cancer treatment by translating clinical practice through research based on data and biospecimens collected from the prospective SWOG S1714 clinical trial. This research aims to discover biomarkers such as kinetics, genetics, and metabolomics associated with taxane-induced peripheral neuropathy to identify patients at higher risk and to create personalized treatment approaches. He is also a strong advocate for DPYD testing to prevent severe fluoropyrimidine toxicity and has published several manuscripts on the clinical utility of pre-treatment DPYD testing. He is currently accepting PhD students.

Research Interests

Experience

Awards